Oregon Public Employees Retirement Fund Acquires 7,208 Shares of Cencora, Inc. $COR

Oregon Public Employees Retirement Fund raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 48.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,169 shares of the company’s stock after acquiring an additional 7,208 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Cencora were worth $6,928,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. State of Alaska Department of Revenue raised its stake in shares of Cencora by 5.1% during the 3rd quarter. State of Alaska Department of Revenue now owns 37,177 shares of the company’s stock valued at $11,618,000 after purchasing an additional 1,810 shares during the period. Capital Investment Advisors LLC increased its position in shares of Cencora by 109.0% during the third quarter. Capital Investment Advisors LLC now owns 2,195 shares of the company’s stock valued at $686,000 after buying an additional 1,145 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Cencora by 10.9% in the third quarter. Nisa Investment Advisors LLC now owns 77,105 shares of the company’s stock worth $24,098,000 after buying an additional 7,605 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its position in shares of Cencora by 0.4% in the third quarter. Ferguson Wellman Capital Management Inc. now owns 209,249 shares of the company’s stock valued at $65,397,000 after acquiring an additional 733 shares during the period. Finally, Baker Ellis Asset Management LLC grew its stake in Cencora by 9.4% during the third quarter. Baker Ellis Asset Management LLC now owns 2,494 shares of the company’s stock valued at $779,000 after acquiring an additional 214 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

COR has been the topic of several recent analyst reports. Bank of America lowered their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Mizuho boosted their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $379.50.

Cencora Price Performance

Shares of Cencora stock opened at $335.73 on Friday. The business has a 50 day moving average of $349.89 and a 200 day moving average of $318.10. Cencora, Inc. has a 52 week low of $233.61 and a 52 week high of $377.54. The company has a market cap of $65.13 billion, a PE ratio of 42.23, a P/E/G ratio of 1.60 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the firm earned $3.34 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is currently 30.19%.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the transaction, the chief executive officer owned 68,059 shares in the company, valued at approximately $23,374,863.55. This represents a 6.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 20,317 shares of company stock valued at $7,009,260. 10.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.